Heijl Anders

Jóhannesson Gauti, Lindén Christina, Aspberg Johan, Andersson-Geimer Sabina, Heijl Anders, Bengtsson Boel et al.

This 5-year study found no difference in ocular surface disease between mono- and multitherapy glaucoma patients. However, a subgroup had severe OSD, suggesting laser or preservative-free drops for them.

Bengtsson Boel, Heijl Anders, Aspberg Johan, Jóhannesson Gauti, Andersson-Geimer Sabina, Lindén Christina

Bengtsson Boel, Heijl Anders, Aspberg Johan, Jóhannesson Gauti, Andersson-Geimer Sabina, Lindén Christina

This study compared intensive versus standard glaucoma treatment. Intensive treatment showed better visual field outcomes, especially in patients with higher initial IOP, suggesting it may benefit this subgroup.

Heijl Anders

Heijl Anders, Peters Dorothea, Bengtsson Boel

Rasmuson Erika, Bengtsson Boel, Lindén Christina, Heijl Anders, Aspberg Johan, Andersson-Geimer Sabina et al.

Long-term, laser trabeculoplasty effectively lowered IOP for years in multi-treated glaucoma patients, but only if pre-laser IOP was 15mmHg or higher, guiding treatment selection.

Heijl Anders, Peters Dorothea, Bengtsson Boel

Long-term follow-up of early glaucoma showed delaying treatment didn't cause worse vision impairment, though immediate treatment slightly reduced visual field loss.

Aspberg Johan, Heijl Anders, Bengtsson Boel

This study estimated the preclinical detectable phase (PCDP) for open-angle glaucoma to be approximately 10 years, suggesting that screening programs could effectively use intervals of around 5 years.

Peters Dorothea, Heijl Anders, Andersson-Geimer Sabina, Aspberg Johan, Lindén Christina, Jóhannesson Gauti et al.

This study found that visual field damage near fixation in early glaucoma did not significantly impact patients' vision-related quality of life, suggesting early central defects may be well-tolerated.

Bengtsson Boel, Lindén Christina, Heijl Anders, Andersson-Geimer Sabina, Aspberg Johan, Jóhannesson Gauti

This study found intensive initial glaucoma treatment (multiple drugs + laser) significantly slowed visual field progression compared to monotherapy over three years, suggesting better early disease control.

Heijl Anders, Patella Vincent Michael, Flanagan John G, Iwase Aiko, Leung Christopher K, Tuulonen Anja et al.

This study found false positive rates weakly affect visual field results, except in severe glaucoma, suggesting current reliability criteria for these tests may need revision.

Aspberg Johan, Heijl Anders, Bengtsson Boel

Population glaucoma screening in Sweden reduced bilateral low vision and blindness by approximately 50%. This suggests screening can significantly preserve sight.

Rasmuson Erika, Bengtsson Boel, Lindén Christina, Heijl Anders, Aspberg Johan, Andersson-Geimer Sabina et al.

Laser trabeculoplasty effectively lowered IOP in newly diagnosed glaucoma patients already on medication, but only if pre-LTP IOP was ≥15 mmHg, suggesting its utility when target pressure isn't met.

Heijl Anders, Brandel Magnus

This paper describes the SSY Engine, a web tool based on research showing a 10-15% reduced glaucoma progression risk for every 1 mmHg IOP drop, aiding future clinical prognostication.

Öhnell Hanna Maria, Heijl Anders, Bengtsson Boel

This 10-year study found no significant difference in retinal nerve fiber layer thinning between healthy and glaucoma patients. OCT progression analyses also showed a high false-positive rate, complicating glaucoma follow-up.

Öhnell HannaMaria, Bengtsson Boel, Heijl Anders

This study found that glaucoma diagnoses made using strict criteria from two initial visual field tests, supported by optic disc findings, were almost always correct, validating early diagnosis.

Aspberg Johan, Heijl Anders, Jóhannesson Gauti, Lindén Christina, Andersson-Geimer Sabina, Bengtsson Boel

Latanoprost effectively lowers IOP in new glaucoma patients, with greater reduction in higher untreated pressures, confirming its role as a first-line treatment.

Heijl Anders, Patella Vincent Michael, Chong Luke X, Iwase Aiko, Leung Christopher K, Tuulonen Anja et al.

SITA Faster, a new visual field test, was studied in glaucoma patients. It significantly reduced test time (30% faster than SITA Fast) while maintaining diagnostic accuracy, offering a more efficient clinical tool.

Oskarsdottir Sigridur E, Heijl Anders, Bengtsson Boel

This study modeled undetected glaucoma risk in a European population, finding it increases with age and IOP, yet many undetected cases have normal IOP, aiding targeted screening.

Lindén Christina, Heijl Anders, Jóhannesson Gauti, Aspberg Johan, Andersson Geimer Sabina, Bengtsson Boel

This study found multi-therapy significantly reduced initial IOP more than mono-therapy in newly diagnosed glaucoma, especially with higher baseline IOPs, improving target IOP attainment.

Bengtsson Boel, Heijl Anders, Johannesson Gauti, Andersson-Geimer Sabina, Aspberg Johan, Lindén Christina

This study compares intensive versus standard initial glaucoma treatment to determine which better preserves visual field and quality of life long-term.

Öhnell HannaMaria, Heijl Anders, Anderson Harald, Bengtsson Boel

This study found that visual field progression was detected much earlier than optic disc changes in manifest open-angle glaucoma, regardless of disease stage, highlighting its primacy in monitoring.

Bengtsson Boel, Heijl Anders

This study found that early glaucoma patients starting IOP-lowering treatment showed no significant visual field improvement compared to untreated patients over three months. This suggests that initial treatment doesn't immediately reverse or stabilize early visual field loss.

Öhnell HannaMaria, Heijl Anders, Brenner Lena, Anderson Harald, Bengtsson Boel

This study found that in manifest glaucoma, visual field progression often precedes optic disc changes, but in eyes without baseline field loss, structural and functional changes progress similarly.

Peters Dorothea, Heijl Anders, Brenner Lena, Bengtsson Boel

This study found that significant visual field loss (VFI < 50% or MD < -18 dB) in glaucoma patients strongly correlates with reduced vision-related quality of life, highlighting a critical clinical threshold.